Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UroGen PharmaLTS:0XOD -0.14%53 3-1 Month Momentum % is 48.08% as of Sep. 20, 2026. GuruFocus rates LTS:0XOD with a GF Score™ of 53/100 and a GF Value™ of $29.66 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,384 Biotechnology companies, UroGen Pharma ranks better than 92.77% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-20), UroGen Pharma's 3-1 Month Momentum % is 48.08%.
The industry rank for UroGen Pharma's 3-1 Month Momentum % or its related term are showing as below:
LTS:0XOD's 3-1 Month Momentum % is ranked better than 92.77% of 1384
companies
in the Biotechnology industry
Industry Median: 0.44
vs LTS:0XOD: 48.08
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
UroGen Pharma 3-1 Month Momentum % Related Terms
LTS:0XOD vs PVLA, KLRA, VCEL: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, UroGen Pharma's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma (LTS:0XOD) has a 3-1 Month Momentum % of 48.08% as of Sep. 20, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on UroGen Pharma and its competitors. According to the industry distribution chart, UroGen Pharma ranks #100 out of 1384 companies in the Biotechnology industry, placing it in the top 7.2%.
Is UroGen Pharma's 3-1 Month Momentum % too high?
UroGen Pharma's current 3-1 Month Momentum % is 48.08%. The Biotechnology industry median 3-1 Month Momentum % is 0.44. UroGen Pharma's value of 48.08% is 10827.3% above this industry median. Based on the distribution chart, UroGen Pharma ranks #100 out of 1384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, UroGen Pharma has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's 3-1 Month Momentum % compare to PVLA and KLRA?
According to the Biotechnology industry distribution chart, UroGen Pharma ranks #100 out of 1384 companies for 3-1 Month Momentum %. This places UroGen Pharma in the top 7% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 0.44. UroGen Pharma's value of 48.08% is 10827.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 0.44, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UroGen Pharma's current 3-1 Month Momentum % of 48.08% is 10827.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on UroGen Pharma and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 0.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UroGen Pharma's current 3-1 Month Momentum % is 48.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (LTS:0XOD) is currently considered Significantly Overvalued. The stock's GF Value™ is $29.66, compared to a current price of $43.44 — trading 46.5% above its estimated fair value. The current 3-1 Month Momentum % is 48.08% and 10827.3% above the Biotechnology industry median of 0.44. UroGen Pharma's overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For UroGen Pharma (LTS:0XOD), the current 3-1 Month Momentum % is 48.08% as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UroGen Pharma (LTS:0XOD) Overvalued in 2026?
Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued.
The current stock price of $43.44 is trading 46.5% above its estimated GF Value™ of $29.66.
GuruFocus considers UroGen Pharma to be Significantly Overvalued.
Key valuation signals for LTS:0XOD:
3-1 Month Momentum %: 48.08%
GF Value™: $29.66 vs. price of $43.44 (46.5% above fair value)
Industry Position: 10827.3% above the Biotechnology median (#100 of 1384)
No single metric tells the full story. See the LTS:0XOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
53GF Score
Get the complete analysis for LTS:0XOD
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0XOD has been successfully added to your 
